Zainab Khurshid
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zainab Khurshid has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Aaron Chevalier
Section of Computational Biomedicine, Department of Medicine, Boston Unversity Chobanian & Avedisian School of Medicine, Boston, Massachusetts
7 shared publications - Jonathan Hunter Huggins
Department of Mathematics & Statistics Boston University
7 shared publications - Joshua D. Campbell
Boston University Chobanian & Avedisian School of Medicine
7 shared publications - Masanao Yajima
Department of Mathematics & Statistics, Boston University, Boston, Massachusetts
7 shared publications - Shiyi Yang
Division of Computational Biomedicine, Department of Medicine, Boston University School of Medicine, Boston, MA, USA
7 shared publications Nathan Sahelijo
5 shared publications
Latest Publications
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S12)
Identification of rare coding variants associated with Alzheimer’s disease.
Background: Previous whole exome sequencing (WES) studies of Alzheimer’s disease (AD) have identified genome‐wide significant associations with rare variants in several novel genes and highlighted the need for investigations in larger samples. We combined WES and whole genome sequencing (WGS) data assembled by the Alzheimer Disease Sequencing Project (ADSP) to increase the power for detecting associations of AD with rare variants in gene coding regions.Method: We developed an efficient computational pipeline to perform both pre‐merging and post‐merging genotype, variant and sample‐level quality control (QC) on WGS data containing 16,905 individuals and WES data for 20,504 individuals. The resultant sample included participants from European (EA, 11,279 AD cases, 8,924 controls), African American (AA, 2,757 AD cases, 4,336 controls), and Caribbean Hispanic (CH 1,438 AD cases, 3,256 controls) ancestries. We employed GENESIS to test association of AD with 250,465 bi‐allelic QC’d variants using a logistic model including covariates for age, sex, exome capture kit, read length, and ancestry principal components (PCs).Result: In the total sample, variants from APOE and other known AD genes including SORL1 (P = 5.30×10‐7), NECTIN2 (P = 6.94×10‐7), and TREM2 R47H (P = 2.34×10‐13) crossed or neared the study‐wide significance (SWS) threshold of P = 2.00×10‐7 (0.05/250,465). SWS or borderline significant associations were also found with variants in several novel loci including TKTL2 (P = 2.35×10‐8), D2HGDH, (P = 1.09×10‐7), CECR1 (P = 4.02×10‐7), PDHA2 (P = 2.76×10‐7), GOLGA1 (P = 1.72×10‐7), CYLD (P = 1.84×10‐7), and RP11‐243M5.4 (P = 1.37×10‐7). PSEN1 missense mutation G206A (rs63750082) previously associated with early onset AD in the CH group, was significantly associated with late onset AD in the same population (P = 1.58×10‐13). SWS association of AD with APOE was observed in all groups. Significant associations were also observed with variants in SERPINB8 (P = 3.77×10‐9) and FAM171A (P = 7.20×10‐7) in EAs and TLR4 (P = 4.58×10‐7) in CH. Associations with several top‐ranked variants were replicated in the Alzheimer’s Disease Genetics Consortium GWAS dataset that were imputed using the TOPMed reference panel and ADSP 5K WGS dataset.Conclusion: We demonstrated that merging WGS and WES datasets can increase power to detect associations with rare coding variants in genes including ones previously implicated in AD (CYLD and TLR4) and early‐onset stroke (CECR1).
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S12)
Open AccessIdentification of rare coding variants associated with Alzheimer’s disease.
Background: Previous whole exome sequencing (WES) studies of Alzheimer’s disease (AD) have identified genome‐wide significant associations with rare variants in several novel genes and highlighted the need for investigations in larger samples. We combined WES and whole genome sequencing (WGS) data assembled by the Alzheimer Disease Sequencing Project (ADSP) to increase the power for detecting associations of AD with rare variants in gene coding regions.Method: We developed an efficient computational pipeline to perform both pre‐merging and post‐merging genotype, variant and sample‐level quality control (QC) on WGS data containing 16,905 individuals and WES data for 20,504 individuals. The resultant sample included participants from European (EA, 11,279 AD cases, 8,924 controls), African American (AA, 2,757 AD cases, 4,336 controls), and Caribbean Hispanic (CH 1,438 AD cases, 3,256 controls) ancestries. We employed GENESIS to test association of AD with 250,465 bi‐allelic QC’d variants using a logistic model including covariates for age, sex, exome capture kit, read length, and ancestry principal components (PCs).Result: In the total sample, variants from APOE and other known AD genes including SORL1 (P = 5.30×10‐7), NECTIN2 (P = 6.94×10‐7), and TREM2 R47H (P = 2.34×10‐13) crossed or neared the study‐wide significance (SWS) threshold of P = 2.00×10‐7 (0.05/250,465). SWS or borderline significant associations were also found with variants in several novel loci including TKTL2 (P = 2.35×10‐8), D2HGDH, (P = 1.09×10‐7), CECR1 (P = 4.02×10‐7), PDHA2 (P = 2.76×10‐7), GOLGA1 (P = 1.72×10‐7), CYLD (P = 1.84×10‐7), and RP11‐243M5.4 (P = 1.37×10‐7). PSEN1 missense mutation G206A (rs63750082) previously associated with early onset AD in the CH group, was significantly associated with late onset AD in the same population (P = 1.58×10‐13). SWS association of AD with APOE was observed in all groups. Significant associations were also observed with variants in SERPINB8 (P = 3.77×10‐9) and FAM171A (P = 7.20×10‐7) in EAs and TLR4 (P = 4.58×10‐7) in CH. Associations with several top‐ranked variants were replicated in the Alzheimer’s Disease Genetics Consortium GWAS dataset that were imputed using the TOPMed reference panel and ADSP 5K WGS dataset.Conclusion: We demonstrated that merging WGS and WES datasets can increase power to detect associations with rare coding variants in genes including ones previously implicated in AD (CYLD and TLR4) and early‐onset stroke (CECR1).
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
Blood‐derived mitochondrial DNA copy number is associated with Alzheimer’s Disease through the regulation of plasma lipid and amino acid metabolism
Background: Blood‐derived mitochondrial DNA copy number (mtDNA‐CN) is the proxy measurement of mitochondrial function in the peripheral and central systems. Abnormal mtDNA‐CN not only indicates impaired mtDNA replication and transcription machinery but also dysregulated biological processes such as energy and lipid metabolism. However, the relationship between mtDNA‐CN and Alzheimer’s Disease (AD) and the underlying mechanisms of mitochondrial dysfunction in the pathogenesis of AD are still unclear.Method: To investigate the causal relationship between mtDNA‐CN and AD, we performed two‐sample Mendelian randomization (MR) using publicly available summary statistics from GWAS for mtDNA‐CN and AD. Further, we estimated mtDNA‐CN using whole‐genome sequence data from blood samples of 1,521 ADNI participants and used a Cox proportional hazard model, adjusted for age, sex, and study phase, to assess the association between mtDNA‐CN and AD risk. The association of AD biomarkers measured in brain and plasma metabolites with mtDNA‐CN was evaluated using linear regression. We conducted causal mediation analysis to test the natural indirect effects of mtDNA‐CN change on AD risk through the significantly associated biomarkers and metabolites.Result: MR analysis using a profile likelihood approach suggested a causal relationship between decreased blood‐derived mtDNA‐CN and increased risk of AD (OR = 0.71; P = 0.023). Survival analysis showed that decreased mtDNA‐CN was significantly associated with increased risk of conversion from mild cognitive impairment to AD (HR = 0.80; P = 0.0017). We also identified significant associations between mtDNA‐CN and brain glucose metabolism (β = 0.050; P = 0.047) and amyloid‐β (Aβ) (β = 0.069; P = 0.015) and CSF Aβ (β = ‐0.051; P = 0.048). Plasma Aβ was, however, not associated. Several lipid species, amino acids, biogenic amines, and inflammatory proteins in plasma were also significantly associated with mtDNA‐CN. Finally, causal mediation analyses showed that the effect of change in mtDNA‐CN on AD risk is mediated by plasma neurofilament light (β = ‐0.055; P = 0.010), glycine (β = 0.016; P = 0.044), and hexadecenoylcarnitine (β = ‐0.017; P = 0.049).Conclusion: Our study indicates that mtDNA‐CN measured in blood is predictive of AD risk. Associations of mtDNA‐CN with Aβ in CSF and brain, but not plasma, suggest cross‐tissue regulation of mitochondria. Decreased mtDNA‐CN might increase AD risk through lipid and amino acid metabolism. These results also suggest potential development of mtDNA‐CN as a blood‐based biomarker.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S13)
Open AccessBlood‐derived mitochondrial DNA copy number is associated with Alzheimer’s Disease through the regulation of plasma lipid and amino acid metabolism
Background: Blood‐derived mitochondrial DNA copy number (mtDNA‐CN) is the proxy measurement of mitochondrial function in the peripheral and central systems. Abnormal mtDNA‐CN not only indicates impaired mtDNA replication and transcription machinery but also dysregulated biological processes such as energy and lipid metabolism. However, the relationship between mtDNA‐CN and Alzheimer’s Disease (AD) and the underlying mechanisms of mitochondrial dysfunction in the pathogenesis of AD are still unclear.Method: To investigate the causal relationship between mtDNA‐CN and AD, we performed two‐sample Mendelian randomization (MR) using publicly available summary statistics from GWAS for mtDNA‐CN and AD. Further, we estimated mtDNA‐CN using whole‐genome sequence data from blood samples of 1,521 ADNI participants and used a Cox proportional hazard model, adjusted for age, sex, and study phase, to assess the association between mtDNA‐CN and AD risk. The association of AD biomarkers measured in brain and plasma metabolites with mtDNA‐CN was evaluated using linear regression. We conducted causal mediation analysis to test the natural indirect effects of mtDNA‐CN change on AD risk through the significantly associated biomarkers and metabolites.Result: MR analysis using a profile likelihood approach suggested a causal relationship between decreased blood‐derived mtDNA‐CN and increased risk of AD (OR = 0.71; P = 0.023). Survival analysis showed that decreased mtDNA‐CN was significantly associated with increased risk of conversion from mild cognitive impairment to AD (HR = 0.80; P = 0.0017). We also identified significant associations between mtDNA‐CN and brain glucose metabolism (β = 0.050; P = 0.047) and amyloid‐β (Aβ) (β = 0.069; P = 0.015) and CSF Aβ (β = ‐0.051; P = 0.048). Plasma Aβ was, however, not associated. Several lipid species, amino acids, biogenic amines, and inflammatory proteins in plasma were also significantly associated with mtDNA‐CN. Finally, causal mediation analyses showed that the effect of change in mtDNA‐CN on AD risk is mediated by plasma neurofilament light (β = ‐0.055; P = 0.010), glycine (β = 0.016; P = 0.044), and hexadecenoylcarnitine (β = ‐0.017; P = 0.049).Conclusion: Our study indicates that mtDNA‐CN measured in blood is predictive of AD risk. Associations of mtDNA‐CN with Aβ in CSF and brain, but not plasma, suggest cross‐tissue regulation of mitochondria. Decreased mtDNA‐CN might increase AD risk through lipid and amino acid metabolism. These results also suggest potential development of mtDNA‐CN as a blood‐based biomarker.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from The Mutational Signature Comprehensive Analysis Toolkit (musicatk) for the Discovery, Prediction, and Exploration of Mutational Signatures
Mutational signatures are patterns of somatic alterations in the genome caused by carcinogenic exposures or aberrant cellular processes. To provide a comprehensive workflow for preprocessing, analysis, and visualization of mutational signatures, we created the Mutational Signature Comprehensive Analysis Toolkit (musicatk) package. musicatk enables users to select different schemas for counting mutation types and to easily combine count tables from different schemas. Multiple distinct methods are available to deconvolute signatures and exposures or to predict exposures in individual samples given a pre-existing set of signatures. Additional exploratory features include the ability to compare signatures to the Catalogue Of Somatic Mutations In Cancer (COSMIC) database, embed tumors in two dimensions with uniform manifold approximation and projection, cluster tumors into subgroups based on exposure frequencies, identify differentially active exposures between tumor subgroups, and plot exposure distributions across user-defined annotations such as tumor type. Overall, musicatk will enable users to gain novel insights into the patterns of mutational signatures observed in cancer cohorts.Significance:The musicatk package empowers researchers to characterize mutational signatures and tumor heterogeneity with a comprehensive set of preprocessing utilities, discovery and prediction tools, and multiple functions for downstream analysis and visualization.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from The Mutational Signature Comprehensive Analysis Toolkit (musicatk) for the Discovery, Prediction, and Exploration of Mutational Signatures
Mutational signatures are patterns of somatic alterations in the genome caused by carcinogenic exposures or aberrant cellular processes. To provide a comprehensive workflow for preprocessing, analysis, and visualization of mutational signatures, we created the Mutational Signature Comprehensive Analysis Toolkit (musicatk) package. musicatk enables users to select different schemas for counting mutation types and to easily combine count tables from different schemas. Multiple distinct methods are available to deconvolute signatures and exposures or to predict exposures in individual samples given a pre-existing set of signatures. Additional exploratory features include the ability to compare signatures to the Catalogue Of Somatic Mutations In Cancer (COSMIC) database, embed tumors in two dimensions with uniform manifold approximation and projection, cluster tumors into subgroups based on exposure frequencies, identify differentially active exposures between tumor subgroups, and plot exposure distributions across user-defined annotations such as tumor type. Overall, musicatk will enable users to gain novel insights into the patterns of mutational signatures observed in cancer cohorts.Significance:The musicatk package empowers researchers to characterize mutational signatures and tumor heterogeneity with a comprehensive set of preprocessing utilities, discovery and prediction tools, and multiple functions for downstream analysis and visualization.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from The Mutational Signature Comprehensive Analysis Toolkit (musicatk) for the Discovery, Prediction, and Exploration of Mutational Signatures
Mutational signatures are patterns of somatic alterations in the genome caused by carcinogenic exposures or aberrant cellular processes. To provide a comprehensive workflow for preprocessing, analysis, and visualization of mutational signatures, we created the Mutational Signature Comprehensive Analysis Toolkit (musicatk) package. musicatk enables users to select different schemas for counting mutation types and to easily combine count tables from different schemas. Multiple distinct methods are available to deconvolute signatures and exposures or to predict exposures in individual samples given a pre-existing set of signatures. Additional exploratory features include the ability to compare signatures to the Catalogue Of Somatic Mutations In Cancer (COSMIC) database, embed tumors in two dimensions with uniform manifold approximation and projection, cluster tumors into subgroups based on exposure frequencies, identify differentially active exposures between tumor subgroups, and plot exposure distributions across user-defined annotations such as tumor type. Overall, musicatk will enable users to gain novel insights into the patterns of mutational signatures observed in cancer cohorts.Significance:The musicatk package empowers researchers to characterize mutational signatures and tumor heterogeneity with a comprehensive set of preprocessing utilities, discovery and prediction tools, and multiple functions for downstream analysis and visualization.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from The Mutational Signature Comprehensive Analysis Toolkit (musicatk) for the Discovery, Prediction, and Exploration of Mutational Signatures
Mutational signatures are patterns of somatic alterations in the genome caused by carcinogenic exposures or aberrant cellular processes. To provide a comprehensive workflow for preprocessing, analysis, and visualization of mutational signatures, we created the Mutational Signature Comprehensive Analysis Toolkit (musicatk) package. musicatk enables users to select different schemas for counting mutation types and to easily combine count tables from different schemas. Multiple distinct methods are available to deconvolute signatures and exposures or to predict exposures in individual samples given a pre-existing set of signatures. Additional exploratory features include the ability to compare signatures to the Catalogue Of Somatic Mutations In Cancer (COSMIC) database, embed tumors in two dimensions with uniform manifold approximation and projection, cluster tumors into subgroups based on exposure frequencies, identify differentially active exposures between tumor subgroups, and plot exposure distributions across user-defined annotations such as tumor type. Overall, musicatk will enable users to gain novel insights into the patterns of mutational signatures observed in cancer cohorts.Significance:The musicatk package empowers researchers to characterize mutational signatures and tumor heterogeneity with a comprehensive set of preprocessing utilities, discovery and prediction tools, and multiple functions for downstream analysis and visualization.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental File 1 from The Mutational Signature Comprehensive Analysis Toolkit (musicatk) for the Discovery, Prediction, and Exploration of Mutational Signatures
Plate diagram and derivation of bayesian prediction algorithm
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental File 1 from The Mutational Signature Comprehensive Analysis Toolkit (musicatk) for the Discovery, Prediction, and Exploration of Mutational Signatures
Plate diagram and derivation of bayesian prediction algorithm
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental File 1 from The Mutational Signature Comprehensive Analysis Toolkit (musicatk) for the Discovery, Prediction, and Exploration of Mutational Signatures
Plate diagram and derivation of bayesian prediction algorithm
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental File 1 from The Mutational Signature Comprehensive Analysis Toolkit (musicatk) for the Discovery, Prediction, and Exploration of Mutational Signatures
Plate diagram and derivation of bayesian prediction algorithm
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from The Mutational Signature Comprehensive Analysis Toolkit (musicatk) for the Discovery, Prediction, and Exploration of Mutational Signatures
Supplementary Figures and Legends in the order cited in the manuscript
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from The Mutational Signature Comprehensive Analysis Toolkit (musicatk) for the Discovery, Prediction, and Exploration of Mutational Signatures
Supplementary Figures and Legends in the order cited in the manuscript
- Open Access
- 8 October 2021
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 81 (23) , 5813-5817
The Mutational Signature Comprehensive Analysis Toolkit (musicatk) for the Discovery, Prediction, and Exploration of Mutational Signatures
Mutational signatures are patterns of somatic alterations in the genome caused by carcinogenic exposures or aberrant cellular processes. To provide a comprehensive workflow for preprocessing, analysis, and visualization of mutational signatures, we created the Mutational Signature Comprehensive Analysis Toolkit (musicatk) package. musicatk enables users to select different schemas for counting mutation types and to easily combine count tables from different schemas. Multiple distinct methods are available to deconvolute signatures and exposures or to predict exposures in individual samples given a pre-existing set of signatures. Additional exploratory features include the ability to compare signatures to the Catalogue Of Somatic Mutations In Cancer (COSMIC) database, embed tumors in two dimensions with uniform manifold approximation and projection, cluster tumors into subgroups based on exposure frequencies, identify differentially active exposures between tumor subgroups, and plot exposure distributions across user-defined annotations such as tumor type. Overall, musicatk will enable users to gain novel insights into the patterns of mutational signatures observed in cancer cohorts.Significance: The musicatk package empowers researchers to characterize mutational signatures and tumor heterogeneity with a comprehensive set of preprocessing utilities, discovery and prediction tools, and multiple functions for downstream analysis and visualization.
- 8 October 2021
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 81 (23) , 5813-5817
Open AccessThe Mutational Signature Comprehensive Analysis Toolkit (musicatk) for the Discovery, Prediction, and Exploration of Mutational Signatures
Mutational signatures are patterns of somatic alterations in the genome caused by carcinogenic exposures or aberrant cellular processes. To provide a comprehensive workflow for preprocessing, analysis, and visualization of mutational signatures, we created the Mutational Signature Comprehensive Analysis Toolkit (musicatk) package. musicatk enables users to select different schemas for counting mutation types and to easily combine count tables from different schemas. Multiple distinct methods are available to deconvolute signatures and exposures or to predict exposures in individual samples given a pre-existing set of signatures. Additional exploratory features include the ability to compare signatures to the Catalogue Of Somatic Mutations In Cancer (COSMIC) database, embed tumors in two dimensions with uniform manifold approximation and projection, cluster tumors into subgroups based on exposure frequencies, identify differentially active exposures between tumor subgroups, and plot exposure distributions across user-defined annotations such as tumor type. Overall, musicatk will enable users to gain novel insights into the patterns of mutational signatures observed in cancer cohorts.Significance: The musicatk package empowers researchers to characterize mutational signatures and tumor heterogeneity with a comprehensive set of preprocessing utilities, discovery and prediction tools, and multiple functions for downstream analysis and visualization.